Atorvastatin News and Research

RSS

Blood pressure lowering therapy and statins continue to improve survival in patients with hypertension

Blood pressure and cholesterol lowering drugs continue to improve survival in patients with hypertension after more than a decade, according to late breaking results from the ASCOT Legacy study presented at ESC Congress 2018 and published in The Lancet.

28 Aug 2018

Pairing online patient dashboard with 'nudges' to doctors triples statin prescribing rates

Pairing an online patient dashboard with "nudges" to doctors tripled statin prescribing rates in a clinical trial led by Penn Medicine researchers.

27 Jul 2018

Researchers design artificial intelligence system for predicting drug combinations' side effects

Last month alone, 23 percent of Americans took two or more prescription drugs, according to one CDC estimate, and 39 percent over age 65 take five or more, a number that's increased three-fold in the last several decades.

10 Jul 2018

Statins may provide benefits to patients who underwent percutaneous coronary intervention

Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broad population of patients slated to undergo percutaneous coronary intervention, a procedure to clear blocked arteries, in a trial being presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

PCSK9 inhibitor reduces cardiovascular events in ACS patients with high cholesterol

Among patients with persistently high cholesterol despite high-intensity statin therapy, the proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab reduced rates of major adverse cardiovascular events by 15 percent compared with placebo, in a study presented at the American College of Cardiology's 67th Annual Scientific Session.

12 Mar 2018

Study finds no increase in muscle-related symptoms when patients are unaware of taking statin therapy

When patients were unaware they were taking statins there was no reported increase in muscle-related symptoms. But, when patients knew they were taking a statin, they were more likely to report symptoms, a finding consistent with the nocebo effect.

4 May 2017

TSRI scientists develop easy method for synthesizing compounds with potential to treat lung disorders

Chemists at The Scripps Research Institute have developed a broad and strikingly easy method for synthesizing a class of molecules that have demonstrated value as pharmaceuticals.

17 Apr 2017

Common anti-cholesterol drugs show promise for reducing Alzheimer's disease risk

Common anti-cholesterol drugs show promise for reducing the risk of Alzheimer's disease, a University of Southern California-led study of Medicare data reveals.

14 Dec 2016

High-intensity statin treatments increase survival rates in patients with cardiovascular disease

A large national study has confirmed the value of high-intensity statin treatments for people with cardiovascular disease, according to researchers at the Stanford University School of Medicine.

9 Nov 2016

Research shows how mitochondrial targeting antioxidants could help treat osteoarthritis

High cholesterol might harm more than our cardiovascular systems. New research using animal models, published online in The FASEB Journal, suggests that high cholesterol levels trigger mitochondrial oxidative stress on cartilage cells, causing them to die, and ultimately leading to the development of osteoarthritis.

17 Oct 2016

New controlled drug release system could revolutionize success rate of vascular bypasses

Coronary or peripheral bypasses are the most frequently performed vascular operations. Although one million patients per year and around the world, undergo this intervention, its failure rate reaches 50%, because of poor vessel healing, leading to vessel graft occlusion.

13 Jun 2016

Women less likely to stick to cardiac rehabilitation program than men, study finds

Cardiovascular disease is a leading cause of disability globally. Participation in cardiac rehabilitation programs is associated with significantly lower death, but evidence suggests that women are significantly less likely to stick to a cardiac rehabilitation program than men, according to investigators writing in the Canadian Journal of Cardiology.

27 Apr 2016

Evolocumab could be more effective than ezetimibe in lowering cholesterol in statin-intolerant patients

In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab (a PCSK9 inhibitor) was a more effective option to lower cholesterol than ezetimibe in these patients.

4 Apr 2016

Researchers compare lipid-lowering efficacy for two nonstatin therapies in statin-intolerant patients

Steven E. Nissen, M.D., of the Cleveland Clinic, and colleagues identified patients with muscle-related adverse effects from statins and compared lipid-lowering efficacy for two nonstatin therapies, ezetimibe and evolocumab. The study was published online by JAMA, and is being released to coincide with its presentation at the American College of Cardiology's 65th Annual Scientific Session & Expo.

4 Apr 2016

Amgen announces approval of cholesterol-lowering medication Repatha (evolocumab) Injection in Japan

Amgen today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication Repatha (evolocumab) Injection, the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan.

22 Jan 2016

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Sydney-based, ASX listed, biopharmaceutical company, Medlab Clinical Ltd has been granted ethics approval to progress to two separate human trials using its nanotechnology delivery platform.

23 Oct 2015

Resverlogix announces formation of international Clinical Steering Committee for RVX-208 "apabetalone" Phase 3 trial

Resverlogix Corp. is pleased to announce the formation of an international Clinical Steering Committee for the RVX-208 "apabetalone" Phase 3 clinical trial BETonMACE assessing major adverse cardiac events (MACE) in high-risk vascular patients with diabetes mellitus and a recent Acute Coronary Syndrome event. BETonMACE is expected to start in the fall of 2015.

4 Aug 2015

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.

23 Jun 2015

Statins benefit patients undergoing major lung resection, lower major complications

Statins have been shown to reduce complications from cardiovascular surgery. To determine whether statins might also help those undergoing major lung surgeries, a team at Memorial Sloan Kettering Cancer Center conducted a well-designed study that randomized patients to receive either a statin or placebo before and after surgery.